Biotech Bearish Stocks: MannKind Corporation (NASDAQ:MNKD), Exelixis (NASDAQ:EXEL), Inovio Pharmaceuticals (NYSEMKT:INO), EXACT Sciences (NASDAQ:EXAS)



An FDA report raised questions regarding Mannkind Corporation (NASDAQ:MNKD)’s diabetes device Afrezza ahead of an April 1 meeting of outside advisers to the FDA. The drug has yet to be approved by the FDA as there are concerns over certain pharmacology issues that could impact Afreeza’s safety and effectiveness. MannKind Corporation (NASDAQ:MNKD) stock performance was -7.12% in last session and finished the day at $4.83. Traded volume was 26.02million shares in the last session and the average volume of the stock remained 7.89million shares. The beta of the stock remained 1.77. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.60%.

Exelixis Inc. (NASDAQ:EXEL) continuing to drop Friday after the company announced Tuesday night that the Independent Data Monitoring Committee (IDMC) notified the company that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. Exelixis, Inc. (NASDAQ:EXEL) dropped-12.44 percent to $3.38Friday on volume of 22.91million shares. The intra-day range of the stock was $3.37 to $3.91. Exelixis, Inc. (NASDAQ:EXEL) has a market capitalization of $657.80million.

Inovio Pharmaceuticals Inc (NYSEMKT:INO) continues to bask in the glory of its recent high-profile awards in the industry. The company was rare winner of three top awards presented this week in Washington D.C. at the World Vaccine Congress, recognizing outstanding contributors towards the attainment of cancer vaccines and prevention solutions. Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s stock on Mar 28, 2014 reported a decrease of -9.89% to the closing price of $3.28. Its fifty two weeks range is $0.49-$3.95. The total market capitalization recorded $785.92million. The overall volume in the last trading session was 12.51million shares. In its share capital, INO has 208.86million outstanding shares.

Exact Sciences Corporation (NASDAQ:EXAS) said Thursday afternoon that a U.S. Food and Drug Administration advisory panel has unanimously approved its DNA-based, noninvasive colon cancer screening test, paving the way for potential market approval. On Friday, shares of EXACT Sciences Corporation (NASDAQ:EXAS) dropped -6.47% to close the day at $12.86. Company return on investment (ROI) is -33.70% and its monthly performance is recorded as -10.57%. EXACT Sciences Corporation (NASDAQ:EXAS) quarterly revenue growth is 3.29%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone